Glenmark cuts breast cancer drug price

New Delhi: Glenmark Pharmaceuticals Ltd on Thursday said it has slashed the price of breast cancer drug Trastuzumab by bringing its brand Trumab at Rs15,749 for a 440 mg vial from Rs54,000 earlier. Trastuzumab is used in the treatment of a particular type of breast cancer -- HER2-positive, and the company markets its version in India under the brand name ‘Trumab. “The new price of the drug being marketed under the brand name ‘Trumab’, will be Rs15,749 per 440 mg vial.